

Ruby Yun-Ju Huang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/658514/publications.pdf>

Version: 2024-02-01

89
papers

17,498
citations

87723

38
h-index

64668

79
g-index

95
all docs

95
docs citations

95
times ranked

27268
citing authors

#	ARTICLE	IF	CITATIONS
1	Epithelial-Mesenchymal Transitions in Development and Disease. <i>Cell</i> , 2009, 139, 871-890.	13.5	8,592
2	EMT: 2016. <i>Cell</i> , 2016, 166, 21-45.	13.5	3,573
3	Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients. <i>EMBO Molecular Medicine</i> , 2014, 6, 1279-1293.	3.3	612
4	Dual role of autophagy in hallmarks of cancer. <i>Oncogene</i> , 2018, 37, 1142-1158.	2.6	403
5	An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530). <i>Cell Death and Disease</i> , 2013, 4, e915-e915.	2.7	363
6	Early events in cell adhesion and polarity during epithelial-mesenchymal transition. <i>Journal of Cell Science</i> , 2012, 125, 4417-4422.	1.2	286
7	Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer. <i>EMBO Molecular Medicine</i> , 2013, 5, 1051-1066.	3.3	235
8	Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors. <i>European Urology</i> , 2019, 75, 423-432.	0.9	205
9	Lgr5 marks stem/progenitor cells in ovary and tubal epithelia. <i>Nature Cell Biology</i> , 2014, 16, 745-757.	4.6	187
10	Warburg metabolism in tumor-conditioned macrophages promotes metastasis in human pancreatic ductal adenocarcinoma. <i>Oncolmmunology</i> , 2016, 5, e1191731.	2.1	178
11	Screening therapeutic EMT blocking agents in a three-dimensional microenvironment. <i>Integrative Biology (United Kingdom)</i> , 2013, 5, 381-389.	0.6	150
12	Thymoquinone Inhibits Bone Metastasis of Breast Cancer Cells Through Abrogation of the CXCR4 Signaling Axis. <i>Frontiers in Pharmacology</i> , 2018, 9, 1294.	1.6	141
13	AXL-Driven EMT State as a Targetable Conduit in Cancer. <i>Cancer Research</i> , 2017, 77, 3725-3732.	0.4	136
14	GRHL2-miR-200-ZEB1 maintains the epithelial status of ovarian cancer through transcriptional regulation and histone modification. <i>Scientific Reports</i> , 2016, 6, 19943.	1.6	119
15	The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer. <i>Science Signaling</i> , 2016, 9, ra97.	1.6	105
16	FZD7 drives in vitro aggressiveness in Stem-A subtype of ovarian cancer via regulation of non-canonical Wnt/PCP pathway. <i>Cell Death and Disease</i> , 2014, 5, e1346-e1346.	2.7	99
17	A COL11A1-correlated pan-cancer gene signature of activated fibroblasts for the prioritization of therapeutic targets. <i>Cancer Letters</i> , 2016, 382, 203-214.	3.2	99
18	Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease. <i>Gynecologic Oncology</i> , 2004, 94, 197-203.	0.6	97

#	ARTICLE	IF	CITATIONS
19	Stopping transformed cancer cell growth by rigidity sensing. <i>Nature Materials</i> , 2020, 19, 239-250.	13.3	81
20	Up-regulation of interleukin-6 in human ovarian cancer cell via a Gi/PI3K-Akt/NF- κ B pathway by lysophosphatidic acid, an ovarian cancer-activating factor. <i>Carcinogenesis</i> , 2004, 26, 45-52.	1.3	80
21	The <sc>EMT</sc> spectrum and therapeutic opportunities. <i>Molecular Oncology</i> , 2017, 11, 878-891.	2.1	80
22	Rapid Prototyping of Concave Microwells for the Formation of 3D Multicellular Cancer Aggregates for Drug Screening. <i>Advanced Healthcare Materials</i> , 2014, 3, 609-616.	3.9	77
23	Cytoskeletal Proteins in Cancer and Intracellular Stress: A Therapeutic Perspective. <i>Cancers</i> , 2020, 12, 238.	1.7	70
24	Targeting Pathways Contributing to Epithelial-Mesenchymal Transition (EMT) in Epithelial Ovarian Cancer. <i>Current Drug Targets</i> , 2012, 13, 1649-1653.	1.0	68
25	Analysis of gene expression signatures identifies prognostic and functionally distinct ovarian clear cell carcinoma subtypes. <i>EBioMedicine</i> , 2019, 50, 203-210.	2.7	67
26	CSIOVDB: a microarray gene expression database of epithelial ovarian cancer subtype. <i>Oncotarget</i> , 2015, 6, 43843-43852.	0.8	66
27	â€™Lncâ€™ing Wnt in female reproductive cancers: therapeutic potential of long nonâ€™coding RNAs in Wnt signalling. <i>British Journal of Pharmacology</i> , 2017, 174, 4684-4700.	2.7	62
28	Arsenic trioxide prevents radiation-enhanced tumor invasiveness and inhibits matrix metalloproteinase-9 through downregulation of nuclear factor κ B. <i>Oncogene</i> , 2005, 24, 390-398.	2.6	61
29	Modeling of cancer metastasis and drug resistance via biomimetic nano-cilia and microfluidics. <i>Biomaterials</i> , 2014, 35, 1562-1571.	5.7	59
30	The role of GRHL2 and epigenetic remodeling in epithelialâ€™mesenchymal plasticity in ovarian cancer cells. <i>Communications Biology</i> , 2019, 2, 272.	2.0	58
31	The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions. <i>Human Pathology</i> , 2015, 46, 1-8.	1.1	55
32	Activation of STAT3 and STAT5 Signaling in Epithelial Ovarian Cancer Progression: Mechanism and Therapeutic Opportunity. <i>Cancers</i> , 2020, 12, 24.	1.7	53
33	Histotype-specific copy-number alterations in ovarian cancer. <i>BMC Medical Genomics</i> , 2012, 5, 47.	0.7	52
34	Epithelial-to-mesenchymal transition: lessons from development, insights into cancer and the potential of EMT-subtype based therapeutic intervention. <i>Physical Biology</i> , 2019, 16, 041004.	0.8	49
35	Copy Number Variation Analysis of Matched Ovarian Primary Tumors and Peritoneal Metastasis. <i>PLoS ONE</i> , 2011, 6, e28561.	1.1	47
36	Actin cytoskeleton self-organization in single epithelial cells and fibroblasts under isotropic confinement. <i>Journal of Cell Science</i> , 2019, 132, .	1.2	43

#	ARTICLE	IF	CITATIONS
37	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). <i>Clinical Cancer Research</i> , 2020, 26, 5411-5423.	3.2	43
38	Functional relevance of a six mesenchymal gene signature in epithelial-mesenchymal transition (EMT) reversal by the triple angiokinase inhibitor, nintedanib (BIBF1120). <i>Oncotarget</i> , 2015, 6, 22098-22113.	0.8	42
39	Configurable 2D and 3D spheroid tissue cultures on bioengineered surfaces with acquisition of epithelial-mesenchymal transition characteristics. <i>NPG Asia Materials</i> , 2012, 4, e27-e27.	3.8	41
40	RNA-Binding Protein <i>ZFP36L1</i> Suppresses Hypoxia and Cell-Cycle Signaling. <i>Cancer Research</i> , 2020, 80, 219-233.	0.4	40
41	Applications of the Chick Chorioallantoic Membrane as an Alternative Model for Cancer Studies. <i>Cells Tissues Organs</i> , 2022, 211, 222-237.	1.3	40
42	Target cell movement in tumor and cardiovascular diseases based on the epithelial-mesenchymal transition concept. <i>Advanced Drug Delivery Reviews</i> , 2011, 63, 558-567.	6.6	38
43	Linking Epithelial-Mesenchymal Transition to the Well-Known Polarity Protein Par6. <i>Developmental Cell</i> , 2005, 8, 456-458.	3.1	31
44	SNAI1 recruits HDAC1 to suppress SNAI2 transcription during epithelial to mesenchymal transition. <i>Scientific Reports</i> , 2019, 9, 8295.	1.6	31
45	The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer. <i>EMBO Reports</i> , 2018, 19, .	2.0	30
46	Hypoxia-inducible factor-1 β promotes cell survival during ammonia stress response in ovarian cancer stem-like cells. <i>Oncotarget</i> , 2017, 8, 114481-114494.	0.8	28
47	Lysophosphatidic acid induces ovarian cancer cell dispersal by activating Fyn kinase associated with p120 β -catenin. <i>International Journal of Cancer</i> , 2008, 123, 801-809.	2.3	26
48	Functional reservoir microcapsules generated <i>via</i> microfluidic fabrication for long-term cardiovascular therapeutics. <i>Lab on A Chip</i> , 2020, 20, 2756-2764.	3.1	26
49	Intracellular Hyper-Acidification Potentiated by Hydrogen Sulfide Mediates Invasive and Therapy Resistant Cancer Cell Death. <i>Frontiers in Pharmacology</i> , 2017, 8, 763.	1.6	25
50	Inflammatory and mitogenic signals drive interleukin 23 subunit alpha (IL23A) secretion independent of IL12B in intestinal epithelial cells. <i>Journal of Biological Chemistry</i> , 2020, 295, 6387-6400.	1.6	25
51	Cysteine Deprivation Targets Ovarian Clear Cell Carcinoma <i>Via</i> Oxidative Stress and Iron-Sulfur Cluster Biogenesis Deficit. <i>Antioxidants and Redox Signaling</i> , 2020, 33, 1191-1208.	2.5	25
52	Gene expression analysis of matched ovarian primary tumors and peritoneal metastasis. <i>Journal of Translational Medicine</i> , 2012, 10, 121.	1.8	21
53	LNK (SH2B3): paradoxical effects in ovarian cancer. <i>Oncogene</i> , 2015, 34, 1463-1474.	2.6	21
54	Loss of discoidin domain receptor 1 (DDR1) via CpG methylation during EMT in epithelial ovarian cancer. <i>Gene</i> , 2017, 635, 9-15.	1.0	20

#	ARTICLE	IF	CITATIONS
55	Decoding transcriptomic intra-tumour heterogeneity to guide personalised medicine in ovarian cancer. <i>Journal of Pathology</i> , 2019, 247, 305-319.	2.1	18
56	A spatiotemporally defined in vitro microenvironment for controllable signal delivery and drug screening. <i>Analyst</i> , 2014, 139, 4846-4854.	1.7	17
57	The FZD-TWIST 1 axis is responsible for anoikis resistance and tumorigenesis in ovarian carcinoma. <i>Molecular Oncology</i> , 2019, 13, 757-780.	2.1	16
58	Spotlight on the Granules (Grainyhead-Like Proteins) – From an Evolutionary Conserved Controller of Epithelial Trait to Pioneering the Chromatin Landscape. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 213.	1.6	14
59	Putting the BRK on breast cancer: From molecular target to therapeutics. <i>Theranostics</i> , 2021, 11, 1115-1128.	4.6	14
60	High-throughput functional profiling of single adherent cells via hydrogel drop-screen. <i>Lab on A Chip</i> , 2021, 21, 764-774.	3.1	13
61	SNAI1-Driven Sequential EMT Changes Attributed by Selective Chromatin Enrichment of RAD21 and GRHL2. <i>Cancers</i> , 2020, 12, 1140.	1.7	10
62	3D genome organization in the epithelial-mesenchymal transition spectrum. <i>Genome Biology</i> , 2022, 23, .	3.8	10
63	Lysophosphatidic acid modulates the association of PTP1B with N-cadherin/catenin complex in SKOV3 ovarian cancer cells. <i>Cell Biology International</i> , 2012, 36, 833-841.	1.4	9
64	Targeting the AXL signaling pathway in ovarian cancer. <i>Molecular and Cellular Oncology</i> , 2017, 4, e1263716.	0.3	9
65	Prognostic significance of phosphoglycerate dehydrogenase in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 655-665.	1.1	9
66	A reasoned approach towards administering COVID-19 vaccines to pregnant women. <i>Prenatal Diagnosis</i> , 2021, 41, 1018-1035.	1.1	9
67	Modulated TRPC1 Expression Predicts Sensitivity of Breast Cancer to Doxorubicin and Magnetic Field Therapy: Segue Towards a Precision Medicine Approach. <i>Frontiers in Oncology</i> , 2021, 11, 783803.	1.3	9
68	Pharmacological Inhibition of BAD Ser99 Phosphorylation Enhances the Efficacy of Cisplatin in Ovarian Cancer by Inhibition of Cancer Stem Cell-like Behavior. <i>ACS Pharmacology and Translational Science</i> , 2020, 3, 1083-1099.	2.5	8
69	High prevalence of APOA1/C3/A4/A5 alterations in luminal breast cancers among young women in East Asia. <i>Npj Breast Cancer</i> , 2021, 7, 88.	2.3	8
70	Clinical Presentation of Pelvic Tuberculosis Imitating Ovarian Malignancy. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2004, 43, 29-34.	0.5	7
71	Epigenetic derepression converts PPAR γ into a druggable target in triple-negative and endocrine-resistant breast cancers. <i>Cell Death Discovery</i> , 2021, 7, 265.	2.0	7
72	A new dimension in drug discovery: reversing epithelial-mesenchymal transition (EMT). <i>Cell Death and Disease</i> , 2016, 7, e2417-e2417.	2.7	4

#	ARTICLE	IF	CITATIONS
73	Reply to Pontus Eriksson and Gottfrid Sjöndahl's Letter to the Editor re: Tuan Zea Tan, Mathieu Rouanne, Kien Thiam Tan, Ruby Yun-Ju Huang, Jean-Paul Thiery. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors. Eur Urol 2019;75:423-432. European Urology, 2019, 75, e108-e109.	0.9	4
74	Identification of serum cytokine clusters associated with outcomes in ovarian clear cell carcinoma. Scientific Reports, 2020, 10, 18503.	1.6	4
75	Two high-yield complementary methods to sort cell populations by their 2D or 3D migration speed. Molecular Biology of the Cell, 2020, 31, 2779-2790.	0.9	1
76	Case study: Digital spatial profiling of metastatic clear cell carcinoma reveals intra-tumor heterogeneity in epithelial-mesenchymal gradient. , 0, , .		1
77	Evolution of CP2 transcription factors in Hexapoda. Journal of Genetics, 2021, 100, 1.	0.4	1
78	Drug Screening: Rapid Prototyping of Concave Microwells for the Formation of 3D Multicellular Cancer Aggregates for Drug Screening (Adv. Healthcare Mater. 4/2014). Advanced Healthcare Materials, 2014, 3, 620-620.	3.9	0
79	Abstract 1058: Grainyhead-like 2 regulates molecular subtype switching in epithelial ovarian cancer. , 2014, , .		0
80	Abstract POSTER-TECH-1112: Quantitate epithelial-mesenchymal transition in ovarian cancer. , 2015, , .		0
81	Abstract POSTER-BIOL-1301: The receptor tyrosine kinase AXL modulates oncogenic signaling and epithelial mesenchymal transition in epithelial ovarian cancer. , 2015, , .		0
82	Abstract POSTER-THER-1403: FZD7 drives aggressiveness in stem-A subtype of ovarian cancer via regulation of non-canonical Wnt/PCP pathway. , 2015, , .		0
83	Abstract 1430: Transcriptional regulatory loops among SNAI1, TWIST1, ZEB1, and ZEB2 defines the epithelial-mesenchymal transition (EMT) spectrum in epithelial ovarian cancer (EOC). , 2015, , .		0
84	Abstract A30: Frizzled-7 (FZD7)-mediated non-canonical Wnt-Planar Cell Polarity (PCP) signalling pathway as a novel molecular driver for the C5/Proliferative/Stem-A molecular subtype of ovarian cancer.. , 2016, , .		0
85	Sustained Gas6/AXL signaling network in the mes subtype of ovarian cancer as a molecular subtype specific therapeutic target.. Journal of Clinical Oncology, 2016, 34, e17084-e17084.	0.8	0
86	Abstract 4490: Comparisons of genetic alterations of breast cancer between East and West: Special emphases on young patients with ER+/HER2- tumors. , 2016, , .		0
87	KDM4B under hypoxia: a new targetable pathway for epithelial ovarian cancer?. Translational Cancer Research, 2017, 6, S93-S95.	0.4	0
88	Abstract 1820: Synergistic lethality of mAbs with an EMT reversal agent, Nintedanib, in epithelial ovarian cancer. , 2017, , .		0
89	Effect of inhibition of receptor tyrosine kinase AXL by a selective small molecular inhibitor R428 (BGB321) on DNA damage repair response in ovarian cancer cells.. Journal of Clinical Oncology, 2020, 38, e15640-e15640.	0.8	0